Severe spinal cord injury (SCI) damages descending motor and serotonin (5-HT) fiber projections leading to paralysis and serotonin depletion. 5-HT receptors (5-HTRs) subsequently upregulate following 5-HT fiber degeneration, and dendritic density decreases indicative of atrophy. 5-HT pharmacotherapy or exercise can improve locomotor behavior after SCI. One might expect that 5-HT pharmacotherapy acts on upregulated spinal 5-HTRs to enhance function, and that exercise alone can influence dendritic atrophy. In the current study, we assessed locomotor recovery and spinal proteins influenced by SCI and therapy. 5-HT, 5-HT 2A R, 5-HT 1A R, and dendritic densities were quantified both early (1 week) and late (9 weeks) after SCI, and also following therapeutic interventions (5-HT pharmacotherapy, bike therapy, or a combination). Interestingly, chronic 5-HT pharmacotherapy largely normalized spinal 5-HTR upregulation following injury. Improvement in locomotor behavior was not correlated to 5-HTR density. These results support the hypothesis that chronic 5-HT pharmacotherapy can mediate recovery following SCI, despite acting on largely normal spinal 5-HTR levels. We next assessed spinal dendritic plasticity and its potential role in locomotor recovery. Single therapies did not normalize the loss of dendritic density after SCI. Groups displaying significantly atrophied dendritic processes were rarely able to achieve weight supported open-field locomotion. Only a combination of 5-HT pharmacotherapy and bike therapy enabled significant open-field weigh-supported stepping, mediated in part by restoring spinal dendritic density. These results support the use of combined therapies to synergistically impact multiple markers of spinal plasticity and improve motor recovery.
Introduction
Severe spinal cord injury (SCI) damages descending serotonin (5-HT) projections (Bowker et al., 1981; Skagerberg and Bjorklund, 1985) reducing 5-HT levels in the spinal cord (Hadjiconstantinou et al., 1984) , contributing to the loss of locomotor function below the level of the lesion. Subsequent 5-HT receptor (5-HTR) upregulation occurs caudal to the SCI in regions associated with hindlimb function (e.g. 5-HT 1A R and 5-HT 2A R) (Kong et al., 2011 & Kong et al., 2010 Otoshi et al., 2009; Lee et al., 2007) . This upregulation has been suggested to play a role in pharmacologically mediated hindlimb locomotor function (Nothias et al., 2005; Kao et al., 2006; Dugan and Shumsky, 2015) . Furthermore, SCI also damages descending motor control pathways. Following SCI, the caudal spinal circuitry is deprived of supraspinal input promoting paralysis, dendritic retraction, and dendritic atrophy (Byers et al., 2012; Little et al., 2009; Zhang et al., 2000; Gazula et al., 2004) . Therefore, 5-HTRs and dendritic processes are involved in locomotor function and are potential targets for therapeutic interventions.
Both 5-HT pharmacotherapy and exercise therapy can affect 5-HTRs and dendritic processes in the spinal cord following injury, potentially promoting plasticity. 5-HTR agonists, given acutely or chronically after injury, have been shown to improve locomotor function across many studies (Landry and Guertin, 2004; Landry et al., 2006; Ung et al., 2008; Nothias et al., 2005; Antri et al., 2002 Antri et al., , 2003 Antri et al., 2005; Courtine et al., 2009; Musienko et al., 2011) . Exercise therapy is also utilized to improve function after SCI (Juanjuan et al., 2016; Detloff et al., 2014) . Specifically, bike exercise therapy has been shown to induce plasticity above the level of the lesion, in part, by enhancing BDNF levels (Graziano et al., 2013) . Below the level of the injury, bike exercise therapy also results in reduces spasticity (De Mello et al., 2004; Phadke et al., 2009) , the rate of bone density loss (Lauer et al., 2011) , and lower limb blood pooling (Phillips et al., 1998) . Combining 5-HT pharmacotherapy and bike exercise therapy may further enhance recovery and potentially spinal plasticity, compared to either therapy administered alone.
Further gains in recovery have been realized when 5-HT pharmacology is combined with exercise or training, and these gains are in part facilitated by neural plasticity above the level of the lesion (Ganzer et al., 2013; Foffani et al., 2016; Ganzer et al., 2016; Manohar et al., 2017; van den Brand et al., 2012) . There is evidence that 5-HT pharmacotherapy and exercise treatments may act synergistically to enhance plasticity (Mattson et al., 2004) . And it is possible that these synergistic effects occur throughout the entire neuraxis, including below the level of the lesion. Furthermore, there is little understanding of how these chronic treatments may promote spinal plasticity to facilitate locomotor recovery, either administered separately or as a combination therapy.
In the current study, we assessed locomotor recovery and spinal proteins indicative of plasticity that are influenced by SCI and therapy. 5-HT, 5-HT 2A R, 5-HT 1A R, and dendritic densities were quantified both early (1 week) and late (9 weeks) after SCI, and also following therapeutic interventions (5-HT pharmacotherapy, bike therapy, or a combination). Interestingly, chronic 5-HT pharmacotherapy largely normalized spinal 5-HTR upregulation following injury. Improvement in locomotor behavior was not correlated to 5-HTR density. We next assessed spinal dendritic plasticity and its potential role in locomotor recovery. Single therapies did not normalize the loss of dendritic density after SCI. Groups displaying atrophied dendritic processes were rarely able to achieve weight supported open-field locomotion. Only a combination therapy of 5-HT pharmacotherapy and bike therapy enabled significant open-field weigh-supported stepping, mediated in part by restoring spinal dendritic density. These results support the use of combined therapies to synergistically impact multiple markers of spinal plasticity and improve motor recovery.
Materials & methods

Experimental design
All procedures performed were approved by the Drexel University Institutional Animal Care and Use Committee. Adult female SpragueDawley rats weighing 250-300 g were used for all experiments (N = 41). A subset of rats received a complete spinal transection at T8/ T9 (N = 37). We initially tested responses to acute doses of 5-HTR agonists to determine an optimal combination dose that promotes locomotor output (BBB score) without significant side effects (hindlimb tremor and serotonin syndrome measures) (N = 11). We next performed 2 sets of studies (Fig. 1A, B) . Our first study examined the effect of time after SCI alone on locomotor recovery, spinal 5-HTR densities (5-HT 1A R and 5-HT 2A R), and spinal dendritic (microtubule associate protein 2 or MAP2) plasticity (same animals from acute dose response experiment, N = 11). Our second study examined the effect of therapy after SCI on locomotor recovery, spinal 5-HTR densities, and spinal dendritic plasticity (N = 26). Here we used chronic 5-HT pharmacology and/or exercise therapy as therapeutic interventions. A single set of uninjured animals (Naïve, N = 4) served as tissue for spinal protein assessments for both the effect of time and the effect of therapy studies.
Common method
Spinal transection procedure & animal care
Similar to our previous studies (Ganzer et al., 2013; Ganzer et al., 2016; Foffani et al., 2016; Manohar et al., 2017) , rats received a complete mid-thoracic transection at spinal level T8/T9. Briefly, animals were anesthetized with 5% isoflurane and 2-L of oxygen and maintained at 2-3% isoflurane with 1-L oxygen for the duration of the surgery. A laminectomy at the T8/9 level was performed to expose the spinal cord. A #10 scalpel blade was used to open the dura and pia mater and a #11 scalpel blade was used to make the complete transection of the spinal cord. A fine-tipped microaspiration device was then used to remove 2-3 mm of spinal cord. A collagen matrix, Vitrogen (Cohesion Technology; Encinitas, CA), was injected into the site of the spinal transection. Following surgery, animals were given an intramuscular injection of the antibiotic Pen-G and 5 mL of lactated ringer's subcutaneously before returning to their home cages.
Animals were housed 2 per cage with highly absorbent Alpha-Dri bedding (Shepherd Specialty Papers Inc. Kalamazoo, MI), and cages were kept on warm water blankets. Animals were housed under a 12 h light/dark cycle (lights on at 07:00) with ad libitum access to food and water. Bladder care was given 3 times daily for 2 weeks or until bladder control was regained. If there was any sign of infection, subcutaneous injections of Baytril (0.06 mg/kg) were given twice a day for 7 days.
Drugs
Quipazine (Sigma; St. Louis, MO) and 8-OH-DPAT (Sigma; St. Louis, MO) were dissolved in sterile saline and administered at a volume of 1 mL/kg i.p. & s.c., respectively. Importantly, all 5-HT agonist injection concentrations for a given experimental group are detailed below in the methods. Acute dose response curve experiments utilized a 0.075 and 0.125 mg/kg 5-HT agonist dose to identify an effective agonist Acute dose response on BBB score using a saline (Sal.), 0.075 mg/kg, or 0.125 mg/kg combination dose of the 5-HTR agonists quipazine and 8-OH-DPAT (Late N = 7; Early N = 4). Within group differences: ### different from Sal. at p < 0.001, # different from Sal. at p < 0.05; * different from 0.075 mg/kg at p < 0.05. Across group differences: + different from Early at same dose at p < 0.025. Data displayed is mean ± S.E.M.
concentration. The effect of time and therapy experiments utilized a 0.125 mg/kg 5-HT agonist dose. For all "on-drug" behavioral testing, agonists were administered 5 min before the assessment began.
Open field locomotor scoring
BBB scoring in the open field was used to test behavioral recovery (Basso et al., 1995) . Spontaneous hindlimb motor activity was evaluated for 4 min in a spherical enclosure (minor diameter = 2.5 ft.; major diameter = 3 ft.) and scored by two trained observers with an inter-rater reliability ≥95%, similar to our previous studies (Ganzer et al., 2013; Ganzer et al., 2016; Foffani et al., 2016; Manohar et al., 2017) . BBB scores of 8 or below correspond to various degrees of locomotor-like movements that do not include weight support. BBB scores of 9 or above (to a maximum of 21) indicate some degree of hindquarter weight support starting in stance and progressing to weight-supported stepping.
2.3. Acute dose response test 2.3.1. Acute dose response curves An initial test was performed to determine an optimal 5-HTR agonist combination dose that promoted locomotor output without significant side effects. An acute dose response curve was performed by comparing behavioral responses after an initial injection of saline to a low dose (0.075 mg/kg each) and high dose (0.125 mg/kg each) combination of quipazine and 8-OH-DPAT during weeks 1 (Early, N = 4) and 8 (Late, N = 7) post-SCI. Animals first received the initial injection of saline (Sal.), followed by the low dose combination of drug, and ending with the high dose combination of drug. Each injection was separated by a 24 h washout period. BBB score, hindlimb tremor and caudal serotonin syndrome scores were assessed after each injection. Results of these tests were used to determine drug dose for the effect of time and effect of therapy studies.
Hindlimb tremor
Myoclonus (tremor) can be elicited by hindlimb palpation following SCI. The presence of hindlimb tremors was determined by blinded experimenters during the behavioral tests and hindlimb palpation on the plantar surface of the hindlimbs (Kao et al., 2006) . Tremors were rated on a 4 point scale [0 = no tremor, 1 = mild (detectable on palpation), 2 = moderate (visually noticeable but does not interfere with function), 3 = intense (interferes with function)].
Caudal serotonin syndrome
Depletion of serotonin followed by administration of serotonergic agents has been shown to elicit a group of stereotypies referred to as "the serotonin syndrome" (Martin, 1996) . This consists of a constellation of motor behaviors expressed caudal to the injury including hindlimb spasms and curvature of the tail. Animals were observed in the home cage after drug administration and rated on a 4 point scale [0 = none, 1 = mild (1-2 bouts of short duration), 2 = moderate (1-2 bouts of long duration or 3-5 bouts of short duration), 3 = severe (3 or more bouts of long duration)] for each element of the syndrome which were then added together for the final score (Kao et al., 2006) .
Effect of time study
Our first study examined the effect of time after SCI on locomotor recovery, spinal 5-HTR densities, and spinal dendritic plasticity (Fig. 1A) . We used the same Early (N = 4) and Late (N = 7) animals to assess locomotor recovery (BBB scoring) and spinal protein densities. BBB scoring was performed after administration of the high dose (0.125 mg/kg each) combination of quipazine and 8-OH-DPAT at the respective time-point (Fig. 1A) . Early and Late animals were sacrificed during weeks 1 and 9 post-SCI, respectively, at least 48 h after drug administration for tissue collection and immunohistochemistry (IHC) (see below for spinal protein IHC details), and compared to protein densities in tissue harvested from Naïve animals (uninjured, N = 4).
Effect of therapy study
Our second study examined the effect of therapy after SCI on locomotor recovery, spinal 5-HTR densities, and spinal dendritic plasticity (Fig. 1B) . These measures were evaluated during weeks 8 and 9 post-SCI in three spinally transected groups receiving: 1) sham pharmacotherapy and exercise therapy (Bike, N = 9), 2) 5-HT pharmacotherapy and sham exercise therapy (5-HT, N = 8) and 3) 5-HT pharmacotherapy and exercise therapy (5-HT + Bike, N = 9) (see below for therapy administration details). Animals here were sacrificed during week 9 post-SCI at least 48 h after drug administration, for tissue collection and IHC (see below for spinal protein IHC details), and compared to protein densities in tissue harvested from the same Naïve animals used for the effect of time study.
Exercise therapy administration
Starting one week after SCI, Bike and 5-HT + Bike animals received passive bicycling exercise using a custom built motor-driven cycling apparatus ( Fig. 1B ; Houle et al., 1999; Graziano et al., 2013) . Rats were suspended horizontally with their feet secured to the pedals. Cycling speed was maintained at 45 revolutions/min and each exercise bout consisted of two 30-min exercise periods with a 10-min rest period in between. Exercise was administered three times per week (Dugan, 2010 ) from 1 to 8 weeks post-SCI (on Mondays, Wednesdays & Fridays). Animals in the 5-HT group were placed on bicycles at the same time periods, but the pedals did not move.
Chronic drug administration
Chronic pharmacotherapy was administered 5 days a week (Monday -Friday) from 2 to 8 weeks post-SCI in the 5-HT and 5-HT + Bike groups ( Fig. 1B ; drug was administered before exercise in the 5-HT + Bike group). Doses of drug consisted of a combination of the 5-HTR agonists quipazine and 8-OH-DPAT at 0.125 mg/kg each. Animals in the Bike group were given injections of saline.
Tissue preparation and spinal protein immunohistochemistry (IHC)
Perfusion & tissue preparation
All animals were sacrificed with Euthasol, perfused transcardially with buffered saline (50 mL), followed by buffered 4% paraformaldehyde (pH 7.4, 500 mL). The spinal cord was then removed and postfixed in the same buffered 4% paraformaldehyde (for a duration of 12 h) and cryoprotected in 30% sucrose (for a duration of 36 h). The spinal cord was removed with spinal roots for anatomical reference. Spinal cord tissue was frozen in Shandon M-1 Embedding Matrix compound (Thermo Scientific), sectioned horizontally at 40 μm thickness and slide mounted for staining. The caudal spinal segments assessed (T12-L1) contain the rhythm generating thoracolumbar spinal gray matter (Kjaerulff and Kiehn, 1996; Kremer and Lev-Tov, 1997) . Alternating sections were stained for the presence of 5-HT, 5-HT 2A R, 5-HT 1A R and MAP2 using avidin-biotin IHC (see below), or Nissl and Myelin to confirm a complete SCI lesion (Fig. 1C ).
IHC controls and staining specificity
All protein staining experiments were run with tissue from multiple groups to control for inter-experiment variability. The antibodies used here were quality control tested by the manufacturer to confirm antibody specificity using standard immunohistochemical techniques (5-HT antibody: cat. # 20080, Immunostar; 5-HT 1A R antibody: cat. # 24504, Immunostar; 5-HT 2A R antibody: cat. # 24288, Immunostar; MAP2 antibody: cat. # M1406, Sigma). In addition, all protein staining experiments here were performed with 3 IHC staining controls to ensure proper antibody performance (IHC staining controls: no primary antibody application, no secondary antibody application, and no primary or secondary antibody application). All controls failed to stain the respective target antigen as expected.
5-HT IHC
Sections of spinal cord tissue were stained for the presence of 5-HT using the following incubations: 1) 0.3% H 2 O 2 & 50% ethanol in phosphate buffer solution (PBS) for 30 mins, 2) PBS rinse, 3) 10% normal goat serum (NGS) and 0.2% Triton in PBS (blocking solution) for 1 h, 4) polyclonal rabbit anti-5-HT primary antibody (Immunostar) diluted 1:80,000 in PBS containing 2% NGS and 0.2% Triton incubated overnight at room temperature, 5) PBS rinse, 6) biotinylated goat antirabbit secondary antibody (Jackson Immuno Inc.) diluted 1:200 in PBS containing 2% NGS incubated for 2 h, 7) PBS rinse, 8) Elite ABC reagent (Vector Labs) for 2 h, 9) PBS rinse, 10) 0.05 M Tris-HCl rinse and 11) 3-3′ diaminobenzidine tetrahydrochloride (DAB; Sigma) for 20 min.
5-HT 2A R IHC
Sections of spinal cord tissue were stained for the presence of 5-HT 2A R using the following incubations: 1) 0.3% H 2 O 2 & 50% ethanol in PBS for 30 mins, 2) PBS rinse, 3) 5% NGS and 0.1% Triton in PBS (blocking solution) for 1 h, 4) polyclonal rabbit anti-5-HT 2A R primary antibody (Immunostar; antigen corresponding amino acids 22-41 of rat 5-HT 2A R) diluted 1:200 in PBS containing 5% NGS and 0.1% Triton incubated for 64 h at 4°C, 5) PBS rinse, 6) biotinylated goat anti-rabbit secondary antibody (Jackson Immuno Inc.) diluted 1:200 in PBS containing 2% NGS incubated for 2 h, 7) PBS rinse, 8) Elite ABC reagent (Vector Labs) for 2 h, 9) PBS rinse, 10) 0.05 M Tris-HCl rinse and 11) 3-3′ diaminobenzidine tetrahydrochloride (DAB; Sigma) for 50 min.
5-HT 1A R IHC
Sections of spinal cord tissue were stained for the presence of 5-HT 1A R using the following incubations: 1) 0.3% H 2 O 2 & 50% ethanol in PBS for 30 mins, 2) PBS rinse, 3) 2% NGS and 0.2% Triton in PBS (blocking solution) for 1 h, 4) polyclonal rabbit anti-5-HT 1A R primary antibody (Immunostar; recognizes the amino acids 294-312 on the third intracellular loop of rat 5-HT 1A R) diluted 1:300 in PBS containing 2% NGS and 0.2% Triton incubated overnight at room temperature, 5) PBS rinse, 6) biotinylated goat anti-rabbit secondary antibody (Jackson Immuno Inc.) diluted 1:200 in PBS containing 2% NGS for 2 h, 7) PBS rinse, 8) Elite ABC reagent (Vector Labs) for 2 h, 9) PBS rinse, 10) 0.05 M Tris-HCl rinse and 11) 3-3′ diaminobenzidine tetrahydrochloride (DAB; Sigma) for 50 min.
MAP2 IHC
Sections of spinal cord tissue were stained for the presence of MAP2 using the following incubations: 1) 0.3% H 2 O 2 & 50% ethanol in PBS for 30 mins, 2) PBS rinse, 3) 2% normal horse serum (NHS) and 0.1% Triton in PBS (blocking solution) for 1 h, 4) monoclonal mouse anti-MAP2 primary antibody (Sigma; clone AP20; recognizes only high molecular weight forms (MAP2a +2b) and is insensitive to phosphorylation state) diluted 1:500 in PBS containing 2% NHS and 0.1% Triton incubated for 48 h at 4°, 5) PBS rinse, 6) biotinylated horse anti-mouse secondary antibody (Vector Labs) diluted 1:200 in PBS containing 2% NHS for 2 h, 7) PBS rinse, 8) Elite ABC reagent (Vector Labs) for 2 h, 9) PBS rinse, 10) 0.05 M Tris-HCl rinse and 11) 3-3′ diaminobenzidine tetrahydrochloride (DAB; Sigma) for 20 min.
Microscopy & quantification of immunohistochemical stains
All immunostained slides were next dehydrated in a series of alcohol washes and coverslipped using DPX mounting medium (Sigma; St. Louis, MO). Photomicrographs of the 5-HT, 5-HT 2A R, 5-HT 1A R and MAP2 immunostains were taken across all groups (N = 4 for all groups). Using adjacent Nissl and Myelin stained sections, photomicrographs were taken from the rhythm generating T12-L1 segments (Kjaerulff and Kiehn, 1996; Kremer and Lev-Tov, 1997) across the following spinal gray matter regions of interest (ROIs): 1) Dorsal (Rexed lamina I-VI), 2) Intermediate Zone (IMZ; Rexed lamina VII & X), and 3) Ventral (Rexed lamina VIII & IX) (Fig. 1D ). 4-6 photomicrographs were taken from each spinal ROI in each animal. 8-bit gray-scale photomicrographs were taken using a 20× (for the 5-HT, 5-HT 2A R and 5-HT 1A R immunostains) or 100× (for the MAP2 immunostain) objective. Images were processed in Image J (NIH). Only spinal gray matter was selected for image analysis for all immunostains. MAP2 is primarily found in the somatodendritic region of neurons (Harada et al., 2002) . Immunoreactive somata were excluded manually during MAP2 image processing similar to previous study (Adkins-Muir and Jones, 2003) in Image J using custom drawn ROIs. This was done to ensure that only dendritic processes contributed to the MAP2 dendritic density quantification. Background values were calculated and subtracted within images. A threshold value was then chosen for a given immunostain so that only immunopositive elements of the spinal gray matter were selected for image analysis similar to previous studies (Kao et al., 2006; Kong et al., 2010) . This threshold value was kept constant for all images across all groups within a given immunostain. The number of pixels occupied by immunolabeled structures within the spinal gray matter was measured. This was then divided by the total amount of pixels in the selected spinal gray ROI to obtain Density (percent of immunopositive pixels).
Data analysis and statistics
Normality tests were performed for each analysis to determine if parametric or nonparametric statistics should be used. For IHC data, each density measure from a single animal was counted as an independent sample. All statistical tests were performed in SPSS v18 (IBM). Unless Bonferroni corrections are noted, an alpha level of 0.05 was accepted for significance.
Effects in the acute dose response curve test on BBB, HL tremor and caudal serotonin syndrome scores were evaluated using two-way repeated measures ANOVAs. The first factor was Time with two levels: Early and Late. The second factor was Dose with three levels: Sal., 0.075 mg/kg, 0.125 mg/kg. Dunnett's post-hoc test was used to determine differences in behavioral scores between dose. Bonferroni corrected post-hoc t-tests were used to determine differences in behavioral scores between weeks for specific doses (alpha level = 0.025).
Effect of time on BBB score was evaluated using a Mann-Whitney U test. Effect of therapy on BBB score was evaluated using a one-way ANOVA. The factor was Therapy Group with three levels: Bike, 5-HT and 5-HT + Bike. BBB scores of 8 or lower correspond to non-weight supported locomotor behaviors (NWS BBB), whereas BBB scores of 9 and above correspond to weight supported locomotor behaviors (WS BBB). For each therapy group, the ratio of NWS BBB scores to WS BBB scores was calculated. Effect of therapy on the proportion of WS BBB scores was assessed using Bonferroni corrected two-proportions tests (alpha level = 0.025).
Effects of time and therapy on 5-HT, 5-HT 2A R and 5-HT 1A R protein densities were each evaluated using separate one-way ANOVAs for the given protein across spinal gray matter ROIs. For the effect of time, the factor for each spinal gray matter ROI protein density assessment was Group with three levels: Naive, Early, and Late. For the effect of therapy, the factor for each spinal ROI protein density assessment was Group with four levels: Naive, Bike, 5-HT, and 5-HT + Bike. Differences between group were determined using Tukey post-hoc tests. Finally, effects of time and therapy on MAP2 dendrite density were each evaluated separately using one-way ANOVAs to assess their impact on anatomical neuronal plasticity (Azmitia et al., 1995; Ramos et al., 2004; Harada et al., 2002) . The Group factors and post-hoc tests for effect of time and therapy on MAP2 were identical to those used for 5-HT protein analyses.
Results
Identifying an optimal dose of a 5-HTR agonist combination
5-HT pharmacology can potentially induce side effects such as hindlimb tremor and serotonin syndrome that can interfere with function following SCI (Kao et al., 2006; Martin, 1996) . Therefore, we first utilized an acute dose response curve to identify an optimal combination dose of the 5-HTR agonists quipazine and 8-OH-DPAT that enhanced open-field locomotor behavior without significant side effects. We measured BBB, hindlimb (HL) tremor, and caudal 5-HT syndrome scores in response to an injection of saline, 0.075 mg/kg, or 0.125 mg/ kg 5-HTR agonist combination dose in Early (week 1 post-SCI) and Late (week 8 post-SCI) animals (Fig. 1E) . Not surprisingly, there was an effect of dose (F(2,18) = 59.1, p < 0.001). Both the 0.075 mg/kg and 0.125 mg/kg acute dose produced a significant increase in BBB score compared to saline in the Early and Late groups (Fig. 1E) . Moreover, in Late animals the 0.125 mg/kg dose produced significantly higher BBB scores compared to the 0.075 mg/kg dose (Fig. 1E ). There was a mild increase of HL tremor scores at the 0.125 mg/kg dose compared to saline in Late animals (p < 0.05, data not shown; F(2,18) = 13.8, p < 0.001). There were no significant effects on any other side effect measures at any other dose across groups (caudal 5-HT syndrome, no significant difference (NSD): F(2,12) = 2.5, p = 0.121). Therefore, the 0.125 mg/kg combination dose of quipazine and 8-OH-DPAT promotes a significant increase in BBB score without deleterious side effects or hindlimb tremors that interfere with behavioral outcome, and was used in the subsequent studies.
Effect of time on locomotor output and spinal 5-HT protein densities
Interestingly, Late animals achieved significantly higher BBB scores compared to Early animals at both acute doses (data repeated from acute dose response curve; Fig. 2A ). However, neither group achieved a weight-supported (WS) BBB score. 5-HT fiber degeneration was not complete in Early animals (week 1 post-SCI; Fig. 2B ), in agreement with previous studies on the time course of 5-HT fiber degeneration following SCI (Hadjiconstantinou et al., 1984; Kong et al., 2011) . However, as expected all 5-HT fibers had degenerated in Late animals (week 9 post-SCI; Fig. 2B ). There were also differences in 5-HTR distribution in both Early and Late animals.
There was no change in Early animal 5-HT 2A R expression compared to Naïve (Fig. 2C) . Early animals displayed a rather circumscribed upregulation of 5-HT 1A R expression in the intermediate zone of the spinal cord compared to Naïve (Fig. 2D) , providing evidence that spinal 5-HTRs can upregulate shortly after SCI. Late animals displayed more extensive 5-HTR changes. There was an upregulation of 5-HT 2A R expression in both the IMZ and Ventral zones compared to Naïve and Early animals ( Fig. 2C ; Dorsal (NSD): F(2,54) = 0.7, p = 0.485; IMZ: F (2,54) = 3.8, p = 0.029; Ventral: F(2,54) = 37.8, p < 0.001) (Ventral exemplar pictures in Fig. 3A) . This significant increase of Ventral 5-HT 2A R density, in contrast to Dorsal, may reflect its predominant functional role in the ventral horn. Late animals also displayed a significant upregulation of 5-HT 1A R across all 3 zones of the cord compared to Naïve animals ( Fig. 2D ; Dorsal: F(2,60) = 10.2, p < 0.001; IMZ: F(2,53) = 7, p = 0.004; Ventral: F(2,57) = 4.7, p = 0.012) (Dorsal exemplar pictures in Fig. 3B ). There was no correlation between 5-HT 2A R or 5-HT 1A R expression and BBB score for Early and Late animals (data not shown), likely due to the modest gains in behavioral recovery. Therefore, 5-HT 2A R and 5-HT 1A R expression is upregulated several weeks after SCI. The incomplete 5-HT fiber degeneration in Early animals may prevent the more widespread and significant upregulation of 5-HT 2A Rs and 5-HT 1A Rs seen in Late animals.
Effect of therapy on locomotor output and spinal 5-HT protein densities
5-HT pharmacotherapy can also be administered chronically in combination with exercise and other therapies to enhance recovery post-SCI (Antri et al., 2002 (Antri et al., , 2003 Antri et al., 2005; Courtine et al., 2009; van den Brand et al., 2012; Ganzer et al., 2013; Foffani et al., 2016; Ganzer et al., 2016; Manohar et al., 2017) . Previous reports have shown significant 5-HTR downregulation following acute or chronic 5-HT pharmacotherapy in supraspinal regions (Gray and Roth, 2001; Riad et al., 2001; Srinivas et al., 2001) . However, it is unclear whether Table 1 for group summary data in figure panels 2C and 2D. P.D. Ganzer et al. Experimental Neurology 304 (2018) 132-142 chronic 5-HT pharmacotherapy also modulates 5-HTR levels in the spinal cord. 5-HTR density was not correlated with behavioral recovery in Early or Late animals. Assessing the impact of chronic 5-HT pharmacotherapy on both spinal 5-HTR changes and behavioral recovery would provide further insight into the underlying mechanism of 5-HT pharmacotherapy.
To assess the effect of therapy after SCI, we measured BBB score and spinal 5-HT, 5-HT 2A R, and 5-HT 1A R densities caudal to the SCI across the Bike, 5-HT, and 5-HT + Bike groups (Naive = uninjured group for the 5-HT protein assessment; data repeated from effect of time study). 5-HT + Bike animals achieved significantly higher BBB scores compared to Bike animals ( Fig. 4A ; F(2,25) = 4.3, p = 0.024). 5-HT + Bike animals also attained a significantly higher proportion of WS BBB scores (7/18) compared to the Bike (0/18) group (Fig. 4B) .
Not surprisingly, there were no detectable 5-HT fibers across groups (week 9 post-SCI; data not shown), as is expected weeks following severe SCI. Bike animals displayed a significant upregulation of both IMZ and Ventral 5-HT 2A R compared to Naïve ( Fig. 4C ; Dorsal: F(3, 66) = 4.8, p = 0.004; IMZ: F(3, 61) = 10.1, p < 0.001; Ventral: F(3, 65) = 54.9, p < 0.001). Interestingly, 5-HT and 5-HT + Bike therapy both downregulated Ventral 5-HT 2A R density compared to Bike ( Fig. 4C ; Ventral exemplar pictures in Fig. 5A ). However, 5-HT animals displayed a significant upregulation of Dorsal and IMZ 5-HT 2A R compared to Naïve animals, demonstrating an incomplete receptor density normalization.
Bike animals displayed a significant upregulation of Dorsal and Ventral 5-HT 1A R density compared to Naïve, 5-HT and 5-HT + Bike animals ( Fig. 4D ; Dorsal: F(3, 64) = 27.2, p < 0.001; IMZ: F(3, 48) = 3.5, p = 0.022; Ventral: F(3, 70) = 39.9, p < 0.001). 5-HT and 5-HT + Bike therapy downregulated Dorsal and Ventral 5-HT 1A R densities compared to Bike ( Fig. 4D ; Dorsal exemplar pictures in Fig. 5B ). 5-HT + Bike animals also displayed a significant upregulation of IMZ 5-HT 1A R compared to Naïve. Therefore, chronically administered 5-HT pharmacotherapy (i.e. 5-HT or 5-HT + Bike therapy) significantly reduced upregulation of the 5-HTR 2A R and 5-HT 1A R seen in Bike animals. This receptor density reduction is widespread in the spinal gray matter, but not complete in all regions. Importantly, these results also confirm that upregulated spinal 5-HTR levels are not necessary for increased locomotor output post-SCI during 5-HTR agonist treatment. Despite near normal 5-HTR levels, 5-HT + Bike animals achieved significant increases in locomotor ability. There was again no correlation between 5-HT 2A R or 5-HT 1A R expression and BBB score across groups (data not shown), further supporting our initial conclusion that spinal 5-HTR density does not predict behavioral response to 5-HT agonists following SCI.
Effect of time and therapy on spinal dendritic density (MAP2)
5-HT activates molecular pathways associated with synaptic and dendritic plasticity (Fricker et al., 2005; Azmitia et al., 1995; Jitsuki et al., 2011; Lesch and Waider, 2012) . Furthermore, 5-HT pharmacotherapy and neurotrophins upregulated in response to exercise may synergistically interact when administered in combination to further enhance plasticity (Mattson et al., 2004; Foffani et al., 2016) . We expected that over time, SCI alone would produce atrophy of dendritic processes (Zhang et al., 2000) . Furthermore, we hypothesized that the combination 5-HT + Bike therapy would enhance anatomical plasticity caudal to the lesion, restoring dendritic density, which could be partially responsible for the increased open-field locomotor performance. We evaluated the effect of time and therapy on dendritic density (MAP2) caudal to the SCI in the Dorsal, IMZ, and Ventral regions across groups.
There was an effect of SCI on dendritic density in the Early and Late groups ( Fig. 6A-C ; Dorsal: F(2,70) = 7.3, p = 0.001; IMZ: F (2,70) = 7.9, p < 0.001; Ventral: F(2,70) = 5.7, p = 0.005). As expected, both Early and Late animals displayed significant decreases in Dorsal, IMZ, and Ventral MAP2 dendrite density compared to uninjured Naïve animals ( Fig. 6A-C ; exemplar Ventral MAP2 pictures in 7A). This result suggests that the loss of dendritic processes happens quickly after SCI, in agreement with previous studies (Zhang et al., 2000; Gazula et al., 2004) . Therefore, spinal dendritic density decreases precipitously across the gray matter following severe SCI, and the loss is generally maintained weeks later (Fig. 7) .
There was also an effect of therapy on dendritic density ( Fig. 6D-F ; Dorsal: F(3,69) = 21.1, p < 0.001; IMZ: F(3,73) = 23.8, p < .001; Ventral: F(2,82) = 11, p < .001). Bike alone and 5-HT alone displayed significant decreases in Dorsal, IMZ, and Ventral MAP2 dendrite density compared to uninjured Naïve animals ( Fig. 6D-F ; exemplar Ventral MAP2 pictures in 7B). However, the combination of 5-HT + Bike therapy restored dendritic density lost within the first week post SCI, resulting in significantly increased density compared to both Bike (Dorsal, IMZ, and Ventral) and 5-HT animals (Dorsal and Ventral) (Fig. 6D-F) . Therefore, complete midthoracic SCI significantly decreases dendritic density in: 1) animals at both acute (Early) and chronic (Late) stages of SCI, as well as 2) animals receiving a single therapeutic intervention (Bike or 5-HT). The combination 5-HT + Bike therapy restored dendritic density, which was accompanied by a lack of 5-HTR upregulation and increases in open-field weight-supported locomotor P.D. Ganzer et al. Experimental Neurology 304 (2018) 132-142 recovery.
Discussion
Here we examined the effect of time and therapy on post-SCI locomotor recovery, spinal 5-HTR plasticity (5-HT 2A R, 5-HT 1A R), and dendritic plasticity (MAP2). As previously reported, dendritic atrophy occurred early after SCI, and was maintained weeks later without therapy. Furthermore, complete 5-HT fiber degeneration was accompanied by upregulated spinal 5-HTRs. Acute administration of combinations of 5-HTR agonists were studied to identify doses that enhanced locomotor output without significant side effects. Importantly, an acute dose of 5-HTRs acted on upregulated 5-HTRs to improve locomotor behavior late (week 9 post-injury) after SCI compared to early (week 1 post-injury). Yet, the locomotor improvement was not sufficient to allow animals to achieve weight-supported stepping, likely due to the significant atrophy of spinal dendritic processes caudal to the SCI. A combination therapy of 5-HT + Bike promoted significant increases in open-field weight-supported stepping while largely normalizing 5-HTR levels and reversing dendritic atrophy. Behavioral recovery was not correlated to 5-HTR density regardless of therapy. These results provide important insights into how combination therapies can act on different anatomical substrates and work together to improve behavioral outcome better than either therapy alone (Foffani et al., 2016) .
The 5-HTR density results presented here do not necessarily represent an exact quantitation of spinal protein levels. Alternative molecular methods (western blot or HPLC) would allow for exact spinal protein level measurement. However, knowledge of the spatial distribution of 5-HTR changes within the spinal gray matter is essential for understanding and interpreting the effect of receptor plasticity on locomotor performance. Previous studies have assessed cell specific changes in serotonergic function following SCI (Murray et al., 2010; Husch et al., 2012) . However, this was not the focus of the current study. Nonetheless, our measurements of spinal 5-HTR densities following SCI are consistent with previous studies and help to demonstrate a deeper understanding of the potential mechanisms underlying behavioral recovery after SCI. For example, after complete spinal transection at S2, Kong et al. (2011) utilized 5-HT 2A R IHC followed by density measurements to show similar upregulation of this protein caudal to the injury. These investigators reported up to a 5-fold increase 5-HT 2A R protein density in ventral gray caudal to the SCI 4 weeks after injury. More recently, Navarrett et al. (2012) reported an upregulation of 5-HT 2A R mRNA caudal to a midthoracic spinal transection 6 weeks post-SCI. Also, Otoshi et al. (2009) reported an almost 2-fold increase in 5-HT 1A R positive processes in the spinal gray matter caudal to a midthoracic spinal transection 8 weeks post-SCI. Future studies may aim to utilize additional molecular techniques in parallel with IHC approaches to further quantify spinal protein levels. SCI groups displaying both upregulated 5-HTRs and atrophied dendritic processes (i.e. the Late and Bike groups) were never able to Fig. 4 . Effect of therapy on locomotor recovery and spinal 5-HT protein densities. A. At the end of therapy during drug administration, 5-HT + Bike animals achieved significantly higher BBB scores compared to Bike animals (Bike N = 9; 5-HT N = 8; 5-HT + Bike N = 9). Result is from a one-way ANOVA followed by Tukey's post-hoc test. B. 5-HT + Bike animals also achieved a significantly higher proportion of WS (weight-supported) BBB scores when compared to Bike animals (number inset = limbs). Result is from Bonferroni corrected two-proportions tests. C. Chronic 5-HT pharmacotherapy (i.e. 5-HT or 5-HT + Bike therapy) largely prevented the upregulation of spinal 5-HT 2A R densities caudal to the SCI seen in Bike animals (N = 4 for all groups). D. Chronic 5-HT pharmacotherapy (i.e. 5-HT or 5-HT + Bike therapy) also largely prevented the upregulation of spinal 5-HT 1A R densities caudal to the SCI seen in Bike animals (N = 4 for all groups). Results in C and D are from separate one-way ANOVAs. * different at p < 0.05, **p < 0.01, ***p < 0.001. Data displayed is mean ± S.E.M. Please see Table 2 for group summary data in figure panels 4C and 4D. Ganzer et al. Experimental Neurology 304 (2018) 132-142 achieve weight supported open-field locomotion. 5-HTR upregulation is undoubtedly due to the degeneration of 5-HT axons following SCI induced axotomy (Hadjiconstantinou et al., 1984; Kong et al., 2011) . Our findings corroborate with previous studies demonstrating that full 5-HT fiber degeneration is not complete at one week post-SCI (i.e. in Early animals; Hadjiconstantinou et al., 1984; Kong et al., 2011) . SCI also damages descending motor pathways, depriving the caudal spinal circuitry of supraspinal input promoting paralysis, dendritic retraction, and dendritic atrophy (Byers et al., 2012; Little et al., 2009; Zhang et al., 2000; Gazula et al., 2004) . Dendritic arbor density is intimately related to synaptic input density Purves and Hume, 1981) . Reductions in activity can also facilitate synaptic elimination (Constantine-Paton et al., 1990; Constantine-Paton and Cline, 1998) . Modifications to dendritic and synaptic plasticity affects electrophysiological processing of incoming signals (Nusser, 1999; Vetter et al., 2001 ) and subsequent network function post injury (Petruska et al., 2007) . Therefore, dendritic spinal atrophy significantly limited open-field locomotor recovery across groups, regardless of upregulated 5-HTRs for the 5-HTR agonist combination to act upon. It is important to note that locomotion, especially after SCI, involves sensorimotor networks above and below the lesion (Giszter et al., 2010; Shah et al., 2013) . Several studies have shown that cortical reorganization supports recovery following SCI (Manohar et al., 2017; Serradj et al., 2016; Moxon et al., 2014; Foffani et al., 2016; Xerri, 2012; van den Brand et al., 2012; Kao et al., 2006; Giszter et al., 2008) . For example, Moxon et al., 2013 showed that the state of somatosensory cortical networks following neonatal SCI plays a major role in locomotor output induced by the 5-HT 2 R agonist mCPP. Moreover, previous studies have demonstrated that 5-HT and Bike therapy significantly enhance plasticity in somatosensory (Graziano et al., 2013; Ganzer et al., 2013) and motor cortices . Therefore, these results support a model in which combination therapies enhance plasticity at multiple levels of the sensorimotor neuraxis to improve recovery after severe SCI.
Previous reports have shown significant 5-HTR downregulation following acute or chronic 5-HT pharmacotherapy in supraspinal regions (Gray and Roth, 2001; Riad et al., 2001; Srinivas et al., 2001) when the endogenous 5-HT system was intact. However, it was unclear whether daily 5-HT pharmacotherapy would modulate spinal 5-HTR plasticity following SCI that eliminates 5-HT caudal to the lesion. Reversing spinal neuromodulator receptor (norepinephrine, α1) upregulation has been shown previously following SCI using intraspinal implants of locus coeruleus cells, suggesting that spinal receptor densities are plastic and can be upregulated and downregulated following SCI . Effect of time and therapy on MAP2 dendrite density. Early and Late animals displayed a significant loss of MAP2 dendrite density within the Dorsal (A), IMZ (B), and Ventral (C) spinal gray caudal to the SCI compared to Naïve animals (N = 4 for all groups). 5-HT + Bike therapy restored MAP2 dendrite density within the Dorsal (D), IMZ (E), and Ventral (F) spinal gray caudal to the SCI, promoting a significant increase compared to the 5-HT or Bike groups (N = 4 for all groups). Results are from separate one-way ANOVAs. * different at p < 0.05, ** p < 0.01, *** p < 0.001. Data displayed is mean ± S.E.M. P.D. Ganzer et al. Experimental Neurology 304 (2018) 132-142 and treatment (Roudet et al., 1995 & Roudet et al., 1996 . Here, a single daily injection of 5-HTR agonists for several weeks was sufficient to largely prevent the upregulation of 5-HTRs caudal to the SCI throughout the spinal gray matter. Despite near normal 5-HTR levels, 5-HT + Bike animals still achieved open field weight-supported locomotion. Because 5-HT affects cellular neurophysiology via complex G-protein coupled receptor (GPCR) cascades (Hochman et al., 2001) , there are several avenues by which relatively low 5-HTR levels can still promote significant locomotor output post-SCI. Restoring dendritic density as discussed above can mediate synaptic connectivity enhancement related to improved function. Moreover, chronic administration of GPCR agonists have shown increased agonist-receptor affinity and prolonged agonist binding (Birdsong et al., 2013) , allowing activation of receptors to be prolonged and more effective. Furthermore, increases in receptor coupling to intracellular cascades can amplify the effects of delivered agonists (Kenakin, 1995a (Kenakin, , 1995b . Receptor binding and signaling pathway plasticity should be assessed in future studies to further determine the cellular and intracellular effects of post-injury chronic pharmacotherapy.
Post-SCI MAP2 dendritic plasticity can be achieved through a variety of interventions and molecular pathway activations including hormone treatment (González et al., 2009) , hypothermia (Yu et al., 2000) , and glutamate release inhibitor treatment (Springer et al., 1997) . Here we extend these findings demonstrating an enhancement of spinal MAP2 plasticity related to recovery following a combination of 5-HT and exercise therapy. Interestingly, 5-HT treatment alone facilitates MAP2 dendritic plasticity after lesions incompletely eliminating 5-HT in the brain (Azmitia et al., 1995) . This is in contrast to the lack of effect of 5-HT treatment alone on spinal MAP2 shown in this study following complete spinal 5-HT elimination. With regards to exercise, five days of a similar passive hindlimb bicycling following SCI in young (P23) rats was sufficient to increase hindlimb motor neuron dendritic density (Gazula et al., 2004) . However, here following SCI as an adult even longer duration (7 weeks) passive hindlimb bicycling alone was ineffective at restoring dendritic density and enabling weight supported open-field locomotion. This result highlights the differential effect of exercise therapy following neonatal vs. adult SCI. Together, these results from single therapies demonstrate that upregulated 5-HTRs alone are not sufficient to enable weight supported locomotor output following 5-HT pharmacology. Only a combination therapy of 5-HT + Bike normalized 5-HTR and dendritic density to enable weightsupported locomotor ability.
The role of 5-HT (Lesch and Waider, 2012) and exercise (Vaynman and Gomez-Pinilla, 2005) in promoting plasticity is well established. The activation of 5-HTRs induces synaptic and structural plasticity either directly or through neuron-glia interactions (Fricker et al., 2005; Jitsuki et al., 2011; Azmitia et al., 1995; Nishi et al., 1996 & Nishi et al., 1997 Ramos et al., 2004) . Passive bicycling exercise after SCI can increase plasticity by upregulating neurotrophic factors (Côté et al., 2011; Keeler et al., 2012) through modulation of microRNAs . Furthermore, the combination 5-HT + Bike therapy had a greater impact on spinal plasticity compared to either 5-HT or Bike alone, suggesting that these therapies may act synergistically when administered in combination (Mattson et al., 2004) . Therefore, both 5-HT and exercise affect neuronal plasticity. However, these results suggest that combination therapies may be needed to promote significant locomotor recovery following severe SCI as an adult.
Additional work is required to fully understand the mechanisms underlying the combined 5-HT and exercise therapy's support of locomotor recovery after SCI. However, the results reported here demonstrate that continued upregulation of spinal 5-HTRs is not necessary for pharmacologically mediated recovery. Interestingly, spinal dendritic atrophy significantly limited locomotor recovery, regardless of upregulated spinal 5-HTRs for 5-HT pharmacotherapy to act upon. We hypothesize that synergistic combination therapies can maximally enhance spinal plasticity to enable recovery compared to single therapies alone. Furthermore, these findings provide important knowledge for designing pharmacological therapies, and alleviates the burden of requiring dose regimens that preserve the initial upregulation of 5-HTRs after SCI.
